Background: As the survival of HIV-infected individuals has improved due to the
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2.
Compared with HCV mono-infected patients with a PLT less than 150,000 µL, the survival of HIV/HCV co-infected patients was shorter (HCV: 5 years, 97%; 10 years, must be taken into account to establish an optimal therapeutic strategy, including the appropriate timing of liver transplantation in HIV/HCV co-infected patients in Japan.
Introduction
From 1970 until the early 1980's, blood products were imported to Japan, and contaminated blood products were unknowingly used to treat patients with hemophilia.
It was later revealed that these patients were sometimes infected with both HIV and HCV (HIV/HCV co-infection) 1 . However, as the survival of HIV-infected people has improved due to the widespread use of antiretroviral therapy, the mortality due to HCV-related liver disease has increased in HIV/HCV co-infected patients 2, 3 .
The main aim of this investigation was to investigate 1. The status of portal hypertension and the prognosis in HIV/HCV co-infected patients, 2. To establish an appropriate therapeutic strategy for HIV/HCV co-infected patients, including the timing of liver transplantation, in Japan.
Patients and Methods
For Aim 1, routine hematology and blood chemistry tests (general liver function), abdominal ultrasonography and contrast-enhanced CT were performed for 30 patients with HIV/HCV co-infection at Nagasaki University Hospital. To investigate the hepatic functional reserve, liver GSA-scintigraphy and the ICG retention test at 15 min 
Results
In spite of the relatively well-maintained general liver functions, approximately 40% of the HIV/HCV co-infected patients had an impaired hepatic functional reserve (Table 1 ). In addition, in spite of maintained albumin and bilirubin levels, the platelet count was less than 150,000 /ul in 17 co-infected patients, indicating the presence of ongoing portal hypertension.
Even with Child-Pugh A liver function, the HIV/HCV co-infected patients showed a worse prognosis than the HCV mono-infected patients. The prognosis was especially poor in those with lower platelet counts than in the patients with a normal 6 Eguchi et al.
platelet count (Table 2) . When compared with HCV mono-infected patients with a platelet count less than 150,000 ul, the survival of HIV/HCV co-infected patients was much shorter (HCV: 5 years, 97%; 10 years, 86% and HIV/HCV: 5 years, 87%; 10 years, 73%, p<0.05).
Discussion
In HIV/HCV co-infected patients, liver failure due to HCV hepatitis was previously reported to be enhanced by ART-related hepatotoxicity, especially manifesting as non-cirrhotic portal hypertension (NCPH). 4, 5 One of the ART drugs, Didanosin (DDI), has been suspected to under the serious morbidity observed in co-infected patients. 6 Thus, not only in patients with deteriorated liver function, such as in Child-Pugh B or C cases, but also even in Class A cases, the patients' liver function can easily deteriorate abruptly. 7 The natural course of pure NCPH is unknown, because it can be modulated by HCV or other causes, and has only been reported as case series. An important study of "NCPH in HIV mono-infected patients without HCV" was published in 2012. 8 All five patients had portal hypertensive symptoms, such as ascites or variceal bleeding, after receiving antiretroviral therapy.
Therefore, all HIV/HCV co-infected patients should be carefully followed up so as not to miss an opportunity for LT. 9 The prognosis for HIV/HCV co-infected patients was reported to be worse than that for HCV mono-infected patients. 10 In the present study, co-infected patients with a platelet count less than 150,000 µL had an especially poor prognosis, with a shorter survival than mono-infected patients. Our results should be taken into account to establish a therapeutic strategy, while also considering the appropriate timing of liver transplantation in HIV/HCV co-infected patients. In conclusion, the present results should be taken into account to establish an optimal therapeutic strategy, including the appropriate timing of liver transplantation in HIV/HCV co-infected patients. 
